Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MicroPort®

MicroPort Scientific Corporation

微創醫療科學有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 00853)

ESTIMATED INTERIM RESULTS OF SHANGHAI MICROPORT ENDOVASCULAR MEDTECH (GROUP) CO., LTD. FOR THE HALF YEAR ENDED 30 JUNE 2025

The board of directors (the "**Board**") of MicroPort Scientific Corporation (the "**Company**", together with its subsidiaries (the "**Group**")) wishes to inform shareholders of the Company and potential investors that, based on the information currently available to the management, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. ("**EV MedTech**") is expected to achieve revenue of between RMB708.4572 million and RMB787.1747 million for the half year ended 30 June 2025 (the "**Reporting Period**"), representing a decrease of between RMB78.7175 million and RMB0.00 million compared to the same period last year or a period-on-period decrease of between 10.00% and 0.00%. It is estimated that the net profit attributable to the equity owners of EV MedTech for the Reporting Period will be between RMB303.54 million and RMB361.09 million, representing a decrease of between RMB99.9836 million and RMB42.4336 million compared to the same period last year or a period-on-period decrease of between 24.78% and 10.52%.

The above changes were mainly attributable to: the continuous growth of the innovative products of EV MedTech, including Castor® Branched Aortic Stent Graft and Delivery System, Minos® Abdominal Aortic Stent Graft and Delivery System and Reewarm® PTX Drug Balloon Dilatation Catheter, as well as the rapid growth in the hospital admission and implantation volume of new products, particularly the Talos® Thoracic Stent Graft System and Fontus® Branched Surgical Stent Graft System during the Reporting Period, though growth trajectories of sales and profits were modulated during the Reporting Period considering the changes in the market environment in the second half of 2024 and pricing adaptations and promotional campaigns for the products of EV MedTech.

During the Reporting Period, EV MedTech achieved several breakthroughs in its R&D projects. The newly developed generation of Cratos® Branched Aortic Stent Graft system was launched and successfully implanted in clinical settings. Tipspear® Transjugular Intrahepatic Puncture Kit was approved for market launch. The Hector® Thoracic Aorta Multi-Branch Graft Stent System has been officially approved to enter the Special Review of Innovative Medical Device by the National Medical

Products Administration of China (NMPA). This product is used for minimally invasive interventional treatment of thoracic aortic aneurysms involving the three branches of the aortic arch. This is the ninth product from EV MedTech to enter the National "Green Channel" for innovative medical devices, and it has also completed multiple clinical implantations overseas.

To date, the products of EV MedTech have been adopted for clinical use in over 2,700 hospitals across China, covering 31 provinces, autonomous regions, municipalities, Hong Kong and Macao. Its international business has expanded to over 40 countries and regions. During the Reporting Period, Minos® Abdominal Aortic Stent Graft and Delivery System and the Hercules® Balloon Dilatation Catheter were successively granted CE MDR (Medical Device Regulation (EU) 2017/745) certification of the European Union. In the future, EV MedTech will continue to increase its overseas investments, deepen its globalized market presence and provide global patients with higher-quality medical device products and services.

EV MedTech is owned as to 40.32% by the Group and its results are consolidated with the financial statements of the Company. The shares of EV MedTech are listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange.

Shareholders and investors are advised that the above financial information of EV MedTech has been prepared in accordance with Chinese accounting standards and relates solely to the business of EV MedTech, and is unrelated to other subsidiaries of the Group. Such information has not been audited and has not been reviewed by the auditors or the Audit Committee of the Company. Furthermore, (a) intercompany transactions have not been eliminated, (b) the information does not include all businesses of the Group, and (c) it does not represent or fully reflect the businesses or conditions of the Group. **Shareholders and potential investors of the Company are advised to exercise caution when trading in the securities of the Company.**

By Order of the Board
MicroPort Scientific Corporation
Dr. Zhaohua Chang
Chairman

Shanghai, the PRC, 14 July 2025

As at the date of this announcement, the executive Director of the Company is Dr. Zhaohua Chang; the non-executive Directors of the Company are Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida and Ms. Weiqin Sun; and the independent non-executive Directors of the Company are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.

* *For identification purpose only*